Skip to content

The effect of Hydroxyethyl Starch (Voluven) On Hemorrhagic Shock Treatment.

Comparison the effectiveness of hydroxyethyl starch (voluven) solution versus normal saline in hemorrhagic shock treatment in trauma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014052114190N3
Enrollment
100
Registered
2014-06-17
Start date
2013-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhagic Shock. Failure of peripheral circulation NOS

Interventions

Intervention 1: First, a sample of the patient's arterial blood gas (ABG) is drawn. Afterwards the intervention group was treated with 1.000 cc normal saline and 500cc hydroxyethyl starch. After an ho
Treatment - Drugs
First, a sample of the patient's arterial blood gas (ABG) is drawn. Afterwards the intervention group was treated with 1.000 cc normal saline and 500cc hydroxyethyl starch. After an hour, arterial blo
First, a sample of the patient's arterial blood gas (ABG) is drawn. Afterwards the control group was treated with 2.000 cc normal saline. After an hour, arterial blood gas was reevaluated. A questionn

Sponsors

Vice Chancellor for Research and Technology Development-Ahwaz Jondishapur University of Medical Sci
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The study included all patients with traumatic hemorrhagic shock who were referred to the Imam Khomeini hospital in Ahvaz, Iran. Exclusion criteria: Heart failure (reduced heart function with clinical symptoms: orthopnea, exertional dyspnea, MET 50 or drop in Po2 <60 or observed clinical signs of respiratory distress); Renal impairment: decreased renal function (GFR <60 mL/min/1.73 m2 for at least three months, or significant proteinuria); Sepsis: The presence of SIRS (Systemic Inflammatory Response Syndrome) with prove microbial etiology; Severe anemia (Hb <10); Patients who are considered for the diagnosis of non hemorrhagic shock; Patients with a history of sensitivity to the Solutions used in this study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Base Excess. Timepoint: Before and after fluid therapy. Method of measurement: Measured by drawing a sample of arterial blood gas (ABG).

Secondary

MeasureTime frame
Shock Index. Timepoint: after serum therapy. Method of measurement: If the shock index (heart rate / systolic blood pressure) is greater than one is considered positive.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Reza Rafati Navaei

Ahvaz Jundishapur University of Medical Sciences

ali_rafaty@yahoo.com+98 61 1333 3477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026